Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis
Clinical Snapshot
PICO Framework
| P — Population | Adults with moderate-to-severe COPD with type-2 inflammation (eosinophilic phenotype), enrolled in Phase 2 or Phase 3 randomised controlled trials |
| I — Intervention | Type-2-targeted biologics (dupilumab, mepolizumab, benralizumab) targeting IL-4/IL-13 or IL-5 pathways |
| C — Comparator | Placebo (placebo-controlled RCTs only; no head-to-head comparisons) |
| O — Outcomes | Primary: NNT for moderate-to-severe COPD exacerbations (patient-based and event-based). Secondary: pre-bronchodilator FEV1, SGRQ total score, E-RS-COPD score, responder proportions |
Bottom Line
This systematic review and meta-analysis provides the first pooled NNT estimates for type-2-targeted biologics in moderate-to-severe eosinophilic COPD. The headline findings — patient-based NNTs of 12–17 for dupilumab and 11–16 for mepolizumab, and event-based NNTs as low as 3 and 5 respectively — are clinically meaningful if confirmed with adequate statistical precision. Dupilumab demonstrates the most consistent benefit profile, extending beyond exacerbation reduction to improvements in lung function and patient-reported outcomes. Benralizumab shows no clear pooled benefit for exacerbation reduction in this analysis. Important methodological limitations temper confidence: confidence intervals around NNTs are not reported, risk-of-bias assessment is not described, GRADE ratings are absent, and grey literature was not searched. The NNT estimates are scenario-dependent and sensitive to baseline exacerbation rate assumptions. In the Australian context, neither agent is currently TGA-approved or PBS-listed for COPD, making routine use impractical without significant out-of-pocket cost. Clinicians should regard these findings as hypothesis-generating and supportive of emerging evidence, rather than immediately practice-changing. Careful patient selection by eosinophil phenotype remains essential.
Key Findings
P Value: Not reported in abstract
Effect Size: Patient-based NNT: 12–17 for dupilumab; 11–16 for mepolizumab; benralizumab showed no clear exacerbation reduction. Event-based NNT at baseline rate 1.055/year: 3 for dupilumab; 5 for mepolizumab. Dupilumab also associated with improvements in pre-bronchodilator FEV1, SGRQ total score, and E-RS-COPD score.
Primary Outcome: NNT for reduction of moderate-to-severe COPD exacerbations with type-2-targeted biologics
Nnt Or Sensitivity: Patient-based NNT 12–17 (dupilumab) and 11–16 (mepolizumab) across three baseline-risk scenarios; event-based NNT 3 (dupilumab) and 5 (mepolizumab) at baseline annual exacerbation rate of 1.055 per year. Benralizumab: no clear NNT estimable from pooled data.
Confidence Interval: Not reported in abstract; confidence intervals around pooled NNTs and mean differences for secondary outcomes are not available from the published abstract
Clinical Application
Dupilumab and mepolizumab are administered by subcutaneous injection (dupilumab every 2 weeks; mepolizumab monthly), requiring either clinic-based or self-administration infrastructure. Cost is a significant barrier in most healthcare systems. Patient selection requires blood eosinophil count measurement, which is routinely available. Benralizumab, based on these pooled data, does not appear to offer consistent exacerbation benefit in COPD and would not be prioritised for this indication. As of the knowledge cutoff, neither dupilumab nor mepolizumab holds TGA approval specifically for COPD in Australia, and neither is listed on the PBS for this indication. Dupilumab (Dupixent, Sanofi/Regeneron) is TGA-approved and PBS-listed for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Mepolizumab (Nucala, GSK) is TGA-approved and PBS-listed for severe eosinophilic asthma. Prescribers considering off-label use for COPD should be aware of the lack of PBS subsidy, the substantial out-of-pocket cost (estimated >AUD $2,000/month for dupilumab without subsidy), and the absence of RACGP or TSANZ guideline endorsement for this indication. The GOLD 2025 report acknowledges dupilumab as an emerging option for eosinophilic COPD but stops short of a firm recommendation pending further real-world data. Australian respiratory physicians should monitor TGA and PBS submissions closely, as regulatory applications are anticipated given the Phase 3 trial data. Adults with moderate-to-severe COPD and confirmed type-2 inflammatory phenotype (elevated blood eosinophils, typically ≥150–300 cells/μL), with a history of exacerbations despite optimised inhaled therapy. This corresponds to the population enrolled in the BOREAS, NOTUS, MATINEE, and GALATHEA/TERRANOVA trials.
Abstract
In moderate‑to‑severe chronic obstructive pulmonary disease (COPD), the number needed to treat (NNT) quantifies therapeutic benefit but remains underused for type-2-targeted biologics. This meta-analysis quantified the NNT for type-2-targeted biologics in moderate-to-severe COPD and incorporated the recent evidence on exacerbations, lung function, symptoms, health status, and responder outcomes. We searched PubMed, Embase and Web of Science through July 2025 for phase 2 or 3 RCTs of type-2targeted biologics in adults with COPD. The primary outcome was NNT for moderate-to-severe exacerbations; secondary outcomes included pre-bronchodilator forced expiratory volume in 1 s (FEV1), St. George's Respiratory Questionnaire (SGRQ), Evaluating Respiratory Symptoms in COPD (E-RS-COPD), and responder proportions. Pooled ratios and mean differences were synthesized using fixed‑ or random‑effects models. Patient-based NNT was derived from cumulative incidence, event‑based NNT was derived from annualized exacerbation rates. Pooled NNTs were estimated under selected baseline‑risk scenarios. Under three baseline‑risk scenarios, pooled patient‑based NNTs for reducing moderate‑to‑severe COPD exacerbations were 12-17 for dupilumab and 11-16 for mepolizumab, benralizumab showed no clear reduction. Event-based NNTs at a baseline annual exacerbation rate of 1.055 per year were 3 for dupilumab and 5 for mepolizumab. Dupilumab was associated with improvements in pre-bronchodilator FEV1, SGRQ, and E-RS-COPD. For mepolizumab, evidence across these non‑exacerbation outcomes was not consistently observed. In conclusion, pooled patient-based and event-based analyses suggest that both dupilumab and mepolizumab consistently reduce moderate-to-severe exacerbations in eosinophilic or type 2 inflammatory COPD, while improvements in lung function and patient-reported outcomes remain less consistent across biologics and warrant further validation. These findings derive from separate placebo‑controlled trials and should not be interpreted as establishing a comparative efficacy hierarchy among biologics.
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service